

Maximising Opportunities Overcoming Challenges

CNS & Pain




The growing burden of many CNS conditions such as Alzheimer's or Parkinson's disease, multiple sclerosis and chronic pain threatens to overwhelm healthcare resources. While there are many opportunities for new CNS therapeutics, the connections between target and CNS diseases are only slowly being elucidated. tranScrip's expertise and capabilities in CNS & Pain extend across a wide range of indications such as epilepsy, neurodegenerative diseases, stroke, sleep disorders, depression, schizophrenia, ADHD and pain. We cover all phases of the product lifecycle and support and guide our clients to meet their targets even if this means challenging the current clinical and regulatory paradigms.


Diverse Programmes Effective Execution



A snapshot of our recent projects



Insightful Collaborations Seamless Integration



What we will do

When there is a problem or gap, we will become your long-term partner and create a way together to resolve the issue.

Why are we so confident?

Our CNS teams are renowned for integrating seamlessly alongside our clients, providing effective support, delivering strategic insight and innovative approaches to all aspects of CNS drug development, from transitional science through to registration and medical affairs, worldwide.

tranScrip has a proven track record of achievements that include:

- Designing and delivering large, complex, cross-functional CNS programmes
- Serving as the drug development organisation for biotech companies
- Interpreting complex outcomes in clinical trials and steering discussions with the regulatory authorities
- Fielding multi-functional submission teams to author and deliver MAAs and NDAs
- Providing management and oversight for all drug safety needs
- Designing and delivering tailored training programmes for product launches